A clinical trial of CCNU (1-(2 chloroethyl)-3-cyclohexyl-1-nitrosourea) (NSC 79037) in advanced ovarian carcinoma.
CCNU is a useful drug in treating advanced ovarian carcinoma. Of patients with advanced ovarian carcinoma 37% responded favorably to CCNU. Thrombocytopenia was the primary toxic reaction. Clinical trials are in progress to compare the relative effectiveness, the degree of cross-resistance, and the difference in toxicity between CCNU and alkylating agents.
D000477:Alkylating Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008130:Lomustine / Q000009:adverse effects / Q000627:therapeutic use*; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced
D000477:Alkylating Agents; D009607:Nitrosourea Compounds; D008130:Lomustine